BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of December. Details are as follows: Piper Sandler 37th Annual Healthcare Conference Location: New York, NYDate: Tuesday, December 2, 2025 Time: 8:00 AM ET Webcast Link: https://event.webcasts.com/starthere.jsp?ei= ...

Financial Data and Key Metrics Changes - Revenue net of returns for Q3 2025 totaled $146,000, an increase from $126,000 in Q3 2024, while for the nine-month period, it decreased to $302,000 from $600,000 in 2024 [12][13] - Cost of sales increased to $291,000 from $82,000 in the year-ago quarter, primarily due to a $230,000 inventory reserve recorded in Q3 2025 [13] - Gross margins, excluding the inventory reserve, were 42% for Q3 2025 compared to 35% for Q3 2024 [13] - Net loss for Q3 2025 was $2.6 million, compared to $1.4 million for Q3 2024, while the nine-month net loss was $6 million compared to $4.2 million in 2024 [14][15] - Cash and cash equivalents at September 30, 2025, totaled $3.5 million, up from $2 million at December 31, 2024 [15] Business Line Data and Key Metrics Changes - The company is transitioning from the consumer device market to biopharmaceuticals, with a focus on Entolimod and related assets [3][11] - The company recorded reserves for excess and obsolete inventory of $230,000 as part of its exit from the consumer device market [11] - The company has discontinued significant resources toward ClearUP sales, reflecting its strategic shift [12] Market Data and Key Metrics Changes - The company is focusing on building relationships with U.S. and allied governments for Entolimod as a military countermeasure [5][6] - Discussions with BARDA are anticipated to explore stockpiling opportunities for Entolimod [5] Company Strategy and Development Direction - The company has undergone a significant strategic transformation, expanding from bioelectronics to biologic pharmaceuticals with a focus on the immune system [3][4] - The primary commercial opportunity for Entolimod is as a countermeasure for acute radiation syndrome, with plans to advance clinical programs in neutropenia and lymphocyte exhaustion [6][7] - The company is also exploring alternative commercial opportunities for its non-invasive vagus nerve stimulation (VNS) program [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of the transformation and the potential of Entolimod to deliver clinical benefits across multiple organ systems [7][16] - The company aims to advance value creation activities for shareholders while bringing life-saving treatments to patients [17] Other Important Information - The company has completed the transfer of two INDs for Entolimod, enabling further clinical development [6][16] - A new corporate website has been launched to emphasize the transformed mission and expanded clinical pipeline [12] Q&A Session Summary - No specific Q&A session content was provided in the transcript, thus this section is not applicable.

“They’re effectively the immune system’s peacekeepers.” @natashaloder joins “Babbage” to talk about this year’s Nobel prize in physiology or medicine https://t.co/kI7HS8smJe ...

Awards & Recognition - Immunology field sees three immunologists receive the 2025 award for pioneering discoveries [1] - Discoveries are related to the immune system and autoimmune diseases [1]

Researchers have uncovered how the body’s own immune system may be driving the progression of amyotrophic lateral sclerosis, or ALS. It's a breakthrough that could reshape treatment of the fatal disease. https://t.co/CEFQRP6nPg ...

students, parents, and teachers. It's really a great order. I'm a kind of relaxed parent.I don't even know my son's uh class number. When the teacher asked me which class he is, I I just know he's going to 11. He I didn't even know this number of class.I came here representing a group of people which is baby minor society which be called scientist and I actually have a colleague sitting in the audience me is also my colleague and my good friend. Um so um I feel a little bit embarrassed because my slides are ...

Health Implications - Sun exposure may improve heart and immune system health [1] - Avoiding sunburn is crucial when increasing sun exposure [1]

Health & Wellness Benefits - Playing music boosts brainpower, strengthening brain connections [2][3][4] - Consistent music playing enhances the immune system by increasing IgA antibody production [6][7] - Music reduces stress, contributing to overall well-being [8][13] Time Investment & Consistency - Just 5 minutes of daily music practice can yield significant benefits [5] - Consistency is key to experiencing the positive changes from playing music [5] - Music should be approached as an exploration, not a stressful expectation [12] Practical Application - No need to become a professional musician to reap the rewards [4][14] - Focus on enjoying the process of playing music for personal fulfillment [12][15] - Incorporating music into daily routines can improve life [14]

A new neuroimmunology study could have real-world applications for cases in which the body’s immune defences need a boost. Here’s what the researchers found https://t.co/Zzuqzj7VtD ...

Immune System Activation - The study indicates that the immune system can be activated by perceived threats [1] - Activation does not necessarily require physical contact with an infectious agent [1]